eXoZymes (EXOZ) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeonaBio (LONA) has outperformed eXoZymes (EXOZ) over the past year, gaining 45.9% versus a loss of 59.7%. LeonaBio is the larger company by market cap ($54.6 million vs $49.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | LONA |
|---|---|---|
| Share price | $5.33 | $5.79 |
| Market cap | $49.59M | $54.55M |
| 1-day change | 0.00% | +0.70% |
| YTD return | -51.65% | -24.04% |
| 1-year return | -59.68% | +45.94% |
| 5-year return | — | -93.99% |
| EPS (TTM) | $-1.19 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.40 | $14.21 |
| 52-week low | $4.35 | $2.21 |
| Distance from 52-week high | -71.03% | -59.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | — | +199.31% |
| Average volume | 6.97K | 185.45K |
| Shares outstanding | 9.30M | 9.42M |
| Employees | 32 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed EXOZ by 105.6 percentage points over the past year.
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
EXOZ vs LONA FAQ
Which is bigger, eXoZymes or LeonaBio?
LeonaBio (LONA) is larger, with a market capitalization of $54.55M compared with $49.59M for eXoZymes (EXOZ).
Which stock has performed better over the past year, EXOZ or LONA?
LONA returned +45.94% over the past 12 months, compared with -59.68% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.